Older AA/PNH patients who have myeloid driver mutations at baseline and a poor response to nontransplant treatment have a higher risk of progression to sMN. Baseline-prevalent mutations (PIGA/human ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that affects red blood cells, causing symptoms like dark urine, fatigue, and unexplained bruising. Early diagnosis is challenging due to non ...

The FDA approved the complement C5 inhibitor crovalimab (Piasky) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening blood disease. Indicated for PNH in adults and ...

Paroxysmal nocturnal hemoglobinuria leaves red blood cells more vulnerable to destruction. A common side effect is blood clots, known as thrombosis. This is largely preventable with medication to ...

A retrospective analysis surveys the treatment landscape and patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH), illuminating high hospitalization rates and emergency department use ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Patients with paroxysmal nocturnal hemoglobinuria who received iptacopan vs. standard therapy had ...

The first-in-class complement factor D inhibitor danicopan (Voydeya) has been approved by the European Commission as an add-on agent for certain patients with the rare disease paroxysmal nocturnal ...

A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes. Complement ...

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematological disorder affecting all hematopoietic lineages, which lack glycosylphosphatidylinositol (GPI)-anchored membrane proteins ...

You have full access to this article via your institution. In sum, we have identified a molecularly distinct subtype of PNH due to deletion of X-chromosome material. This work was supported in part by ...

NovelMed, a clinical-stage biopharmaceutical company, announced positive 12-week interim results from the ongoing multi-dose phase II trial of Ruxoprubart, a novel complement-targeting immunotherapy, ...